NRC HEALTH NRC
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research
Chart by TradingView
3/9
Piotroski F — financial health
0.03
Altman Z″ — distress risk · distress
—
Dividend payout · n/a
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $137.4M | — | — | $15.7M | $14.0M |
| 2024 | $143.1M | — | — | $19.2M | $31.3M |
| 2023 | $148.6M | — | — | $22.3M | $49.0M |
| 2022 | $151.6M | — | — | $26.4M | $72.0M |
| 2021 | $148.0M | — | — | $40.8M | $85.3M |
| 2020 | $133.3M | — | — | $36.7M | $64.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Berwick Donald M | director | 2026-06-23 | Grant | 7,697 | — |
| Bhandari Parul | director | 2026-06-23 | Grant | 7,697 | — |
| Lockhart Stephen H | director | 2026-06-23 | Grant | 7,697 | — |
| NUNNELLY JOHN N | director | 2026-06-23 | Grant | 7,697 | — |
| Wheeler Penny Ann | director | 2026-06-23 | Grant | 7,697 | — |
| Rau Jason Russell | Executive Vice President | 2026-03-12 | Grant | 60,000 | — |
| HARRISON SHANE R | EVP & Chief Financial Officer | 2026-02-17 | Buy | 8,000 | $12.27 |
| HARRISON SHANE R | EVP & Chief Financial Officer | 2025-12-29 | Tax withheld | 21,271 | $18.66 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.03 (distress)
- Working capital / assets -0.122
- Retained earnings / assets -0.128
- EBIT / assets 0.167
- Equity / liabilities 0.116
Source: SEC EDGAR filings · CIK 0000070487 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.